Fujisawa Pharmaceutical Company, Ltd.

Asahi Kasei Kogyo Kabushiki Kaisha

Hitoshi Yamazaki

Teruo Kyoto Oku

Yoshio Kawai

Hirokazu Tanaka

Natsuko Kayakiri

Takumi Yatabe

Yoshito Abe

Masahiro Neya

Norihiko Shimazaki

Hiroshi Marusawa

Masashi Hashimoto

Kentaro Sato

Yoshikuni Itoh

Kousei Yoshihara

Yuki Sawada

Shigeki Satoh

Tsuyoshi Mizutani

Kazuhiko Ohne

Yasuharu Urano

Yoshimasa Imamura

Kunio Hisatani

Noriko Mukai

Noriko Yoshida

A compound of formula (I) in which Ris halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, Ris amidated carboxy, Ris hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &#x3b1; (TNF &#x3b1;)

Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors

A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substituted lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substituted amino; R is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP-or TNF&agr;-medicated diseases.

Piperazine compounds as inhibitors of MMP or TNF

A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R,is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R,is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R,is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNF&agr;-mediated diseases.

Quinoline compounds as H.sup.+ -ATPases

Benzofuran derivatives useful as inhibitors of bone resorption

Pyrazole derivatives

Pyrazole derivatives useful for inhibiting the production of Interleukin-1 (IL-1) and tumor necrosis factor (TNF) and the like, which can be represented by the following formula: ##STR1## and a pharmaceutical composition containing the same and to uses thereof.

This invention relates to heterocyclic derivatives useful for inhibiting the production of Interleukin-1 (IL-1) and tumor necrosis factor (TNF) and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to uses thereof.

3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

This invention relates to certain 1-heterocycloalkylquinazolin-2,3-dione derivatives, certain pharmaceutically acceptable salts thereof, the process of making those compounds, and the method of using the compounds. The compounds and compositions display effects on the peripheral or central nervous system.

Quinazoline derivatives and their preparation

A compound of the formula: ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halogen, nitro, amino, protected amino, hydroxyamino, lower alkyl, hydroxy, protected hydroxy, sulfamoyl, carboxy, protected carboxy, mercapto, optionally substituted heterocyclic-carbonyl, optionally substituted heterocyclic-(lower)alkyl, lower alkylthio, hydroxy(lower)alkyl or protected hydroxy(lower)alkyl,

Compounds of the formula: ##STR1## are described wherein R.sup.1, R.sup.2, R.sup.3 and A are described in the claims. These compounds show significant dopamine receptor agonist activity.

Quinazoline derivatives

Disclosed is a linear acrylonitrile polymer having a viscosity average molecular weight of at least 50,000, which has a stereoregularity such that the polymer satisfies requirements of I&gt;0.4 and (I+3S)&gt;0.95, wherein I represents the fraction of the isotactic triad and S represents the fraction of the syndiotactic triad. A shaped article is made from a composition comprised of the linear acrylonitrile polymer and a solvent or plasticizer which is selected from a protonic acid and an aqueous solution thereof, an aqueous inorganic salt solution, and a mixture of an organic solvent and an inorganic salt. The fiber made therefrom has an enhanced drawability.

Growing community of inventors

Tsukuba, Japan

Hitoshi Yamazaki